Search

Displaying results 5511 - 5520 of 6831 in total
  1. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  2. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]

  3. Drug

    Guanosine-5'-Triphosphate

    go.drugbank.com/drugs/DB04137
    Experimental

    A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]

  4. Drug

    Cytidine-5'-Triphosphate

    go.drugbank.com/drugs/DB02431
    Experimental

    A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]

  5. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  6. Drug

    ADU-S100

    go.drugbank.com/drugs/DB14722
    Investigational

    ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune … ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system.

  7. Drug

    Tretamine

    go.drugbank.com/drugs/DB14031
    Experimental

    Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.

  8. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  9. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.

  10. Drug

    Nendratareotide uzatansine

    go.drugbank.com/drugs/DB18351
    Investigational

    Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.